Vor Biopharma announces three director resignations, appoints Sarah Reed

Vor Biopharma Inc.

Joshua Resnick, Matthew Patterson, and David Lubner resigned from the Board effective Aug 25-26, 2025; no disagreement cited.
Sarah Reed, General Counsel of RA Capital Management, appointed as independent Class II director effective Aug 27.
Reed receives standard compensation: $40k cash retainer, option to purchase 60k shares, and annual option grants.
Appointment was per securities purchase agreement with RA Capital, which holds >5% of VOR voting stock.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.